Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
27,900
-50 (-0.18%)
Jul 18, 2025, 3:30 PM KST
55.00%
Market Cap306.96B
Revenue (ttm)22.69B
Net Income (ttm)-3.16B
Shares Out11.00M
EPS (ttm)-291.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume233,675
Average Volume405,271
Open27,900
Previous Close27,950
Day's Range27,300 - 28,200
52-Week Range12,550 - 30,750
Betan/a
RSI63.71
Earnings DateAug 8, 2025

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.